Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trelegy vs Relvar in inadequately controlled asthma (China)
CTR20212406Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone furoate + umeclidinium bromide + vilanterol trifenatate in asthma (4 arms), sponsored by GSK. Primary endpoint: Change from baseline in trough FEV1 at Week 12 (FF/UMEC/VI 100/62.5/25 µg vs FF/VI 100/25 µg). Started Sep 2021; status: completed.
02
Drugs
fluticasone furoate + umeclidinium bromide + vilanterol trifenatate
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20212406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212406.